TPST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TPST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Tempest Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $16.94 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.
Total Stockholders Equity is used to calculate Book Value per Share. Tempest Therapeutics's Book Value per Share for the quarter that ended in Jun. 2024 was $0.69. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Tempest Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2024 was 1.20.
The historical data trend for Tempest Therapeutics's Total Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tempest Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Total Stockholders Equity | -68.79 | 36.12 | 18.11 | 26.77 |
Tempest Therapeutics Quarterly Data | |||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Total Stockholders Equity | Get a 7-Day Free Trial | 5.01 | -1.19 | 26.77 | 20.63 | 16.94 |
Tempest Therapeutics (NAS:TPST) Total Stockholders Equity Explanation
1. Total Stockholders Equity is used to calculate Book Value per Share.
Tempest Therapeutics's Book Value per Share for the quarter that ended in Jun. 2024 is
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (16.939 | - | 0) | / | 24.4758 | |
= | 0.69 |
2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.
Tempest Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2024 is
Debt-to-Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (9.584 | + | 10.671) | / | 16.939 | |
= | 1.20 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Tempest Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Justin Trojanowski | officer: Corporate Controller | C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080 |
Nicholas Maestas | officer: VP of Strategy and Finance | 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005 |
Versant Venture Capital Vi, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Side Fund Iv, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Venture Capital Iv, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Ventures Iv, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Thomas Woiwode | director, 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Ventures Vi Gp-gp, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Ventures Vi Gp, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Versant Vantage Ii, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Vantage Ii Gp-gp, Llc | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Vantage Ii Gp, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Thomas W. Dubensky | director, officer: President | C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710 |
Samuel Whiting | officer: Chief Medical Officer | C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080 |
Rock Springs Capital Llc | 10 percent owner | 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202 |
From GuruFocus
By Marketwired • 08-10-2023
By sperokesalga sperokesalga • 05-10-2023
By Value_Insider Value_Insider • 11-10-2022
By GuruFocusNews GuruFocusNews • 07-07-2022
By Marketwired • 10-10-2023
By sperokesalga sperokesalga • 04-28-2023
By GuruFocusNews GuruFocusNews • 07-05-2022
By Marketwired • 09-19-2023
By Marketwired • 10-11-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.